Immunotherapy targeting 4-1BB and its ligand

International Journal of Hematology

Volumn 83, Issue 1, 2006, Pages 23-28

  Vinay, Dass S ^a   Kwon, Byoung S ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Ulsan   (South Korea)

Author keywords

4 1BB; CD11c+CD8 + T cells; CD8+ T cells; Immunotherapy

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CD11C+ CD8+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLONAL ANERGY; COXSACKIE VIRUS; CYTOKINE PRODUCTION; CYTOTOXICITY; GRAFT REJECTION; HERPES SIMPLEX KERATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; VIRUS MYOCARDITIS;

4-1BB LIGAND; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; AUTOIMMUNE DISEASES; CELL SURVIVAL; COXSACKIEVIRUS INFECTIONS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTORS;

EID: 31644447822     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05125     Document Type: Review

References (51)

1. Vinay DS, Kwon BS. Role of 4-1BB in immune regulation. Semin Immunol. 1998;10:481-489.
2. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity. Nat Rev Immunol. 2003;3:609-620.
3. Mittler RS, Juergen F, Megan M. et al. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res. 2004;29:197-208.
4. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311-323.
5. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104: 487-501.
6. Dempsey PW, Doyle SE, He JQ, Cheng, G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003;14:193-209.
7. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756.
8. Takahashi C Mittler RS. Vella AT. Cutting edge: 4-1BB is a bona fide CDST cell survival signal. J Immunol. 1999;162:5037-5040.
9. Melero, I, Johnston JV, Shufford WW, Mittler RS. Chen L. NK1.1 cells express CD137 (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-CD137 monoclonal antibodies. Cell Immunol. 1998;190:167-172.
10. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 2002;169:4230-423
11. Wilcox RA, Chapoval AI, Gorski KS, et al. Expression of functional CD137 receptor by dendritic cells. J Immunol. 2002;168: 4262-4267.
12. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against 4-IBB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685.
13. Foell J, Strahotin S, O'Neil SP. et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB X NZW F1 mice. J Clin Invest. 2003;111:1505-1518.
14. Seo SK, Choi JH, Kim YH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med. 2004;10:1088-1094.
15. Sun Y, Chen HM, Subudhi SK, et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med. 2002;8:1405-1413.
16. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CDS+ T cell proliferation and lead to amplification in vivo of cytotoxicTcell responses. J Exp Med. 1997; 186:47-55.
17. + T cells. Blood. 2004;105: 2206-2213.
18. Kwon BS, Hurtado JC, Lee ZH. et al. Immune responses in 4-1BB (CD137)-deficientmice. J Immunol. 2002;168:5483-5490.
19. Vinay DS, Choi BK, Bae JS, Kim WY. Gebhardt BM. Kwon BS. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower 1L-4 responses. J Immunol. 2004;173: 4218-4229.
20. Futugawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BBL on murine dendritic cells. Int Immunol. 2002; 14:275-276.
21. Diehl L, van Mierlo GJ, den Boer AT, et al. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol. 2002;168:3755-3762.
22. Goodwin RG, Din WS, Davis-Smith T, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol. 1993;23:2631-2641.
23. Laderach D, Wesa A, Galy A. 4-1BB ligand is regulated on human dendritic cells and induces the production of 1L-12. Cell Immunol. 2003;226:37-44.
24. Seo SK, Gebhardt BM, Lim HY, et al. Murine keratocytes function as antigen-presenting cells. Eur J Immunol. 2001;31:3318-3328.
25. Pollok KE, Kim YJ, Hurtado JC, Zhou Z, Kim KK, Kwon BS. 4-1BB T cell antigen binds to mature B cells and macrophages and co-stimulates anti-μ-primed splenic B cells. Eur J Immunol. 1994; 24:367-374.
26. DeBenedette MA, Wen T, Bachmann MF, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-IBBL in skin allograft rejection and in the cytotoxicT cell response to influenza virus. J Immunol. 1999; 163:4833-4841.
27. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109:651-659.
28. Pollok KE, Kim YJ, Zhou Z. et al. Inducible T cell antigen 4-1BB: analysis of expression and function. J Immunol. 1993;150:771-781.
29. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation: comparison with the costimulatory molecule CD28. J Immunol. 1995;155:3360-3367.
30. Pollok KE, Kim SH, Kwon BS. Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4. Eur J Immunol. 1995;25:488-494.
31. lck. J Immunol. 1993;151: 1255-1262.
32. Hellstrom KE, Hellstrom I. Therapeutic vaccination with tumor cells that engage CD137. J Mol Med. 2003;81:71-86.
33. Ito F, Li Q, Shreiner AB, et al. Anti-CD 137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004;64:8411-8419.
34. Mittler RS, Bailey TS. Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med. 1999;190:1535-1540.
35. Ye Z, Hellslrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8:343-348.
36. Maus MV, Thomas AK, Leonard DGB, el al. Ex vivo expansion of polyclonal and antigen-specific cyloloxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28, and 4-1BB. Nat Biotechnol. 2002;20:143-148.
37. Sun Y, Lin X, Chen HM, et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol. 2002;168:1457-1465.
38. Sun Y, Blink SE, Chen JH, Fu YX. Regulation of follicular dendritic cell networks by activated T cells: the role of CDl 37 signaling. J Immunol. 2005;175:884-890.
39. Pan PY, Gu P, Li Q, Xu D, Weber K, Chen SH. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J immunol. 2004;172:4779-4789.
40. Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CDS T cells in a CD40-dependent manner. J Immnnol. 2002;169:1792-1800.
41. Myers L, Takahashi C, Mittler RS, Rossi RJ, Vella AT. Effector CDS T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Natl Acad Sci USA. 2003;100:5348-5353.
42. Zhang H, Merchant MS, Chua KS, et al.Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther, 2003;2:579-586.
43. DeFina R, Christopher K, He H, et al. Analysis of costimulation by 4-1BBL, CD40L, and B7 in graft rejection by gene expression profiles. J Mol Med. 2003;81:655-663.
44. Wieth C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol. 2003;170:2912-2922.
45. Yoshida H, Katayose Y, Unno M. et al. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol Immunother. 2003;52:97-106.
46. α-transgenic mice. J Immunol. 2001;167:2671-2676.
47. Tan JT, Whitmire JK, Murali-Krishna K, et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol. 2000;164:2320-2325.
48. Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CDS T cell responses. J Immunol. 1999;163:4859-4868.
49. Seko Y, Takahashi N, Oshima H, et al. Expression of tumor necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-IBBL in murine hearts with acute myocarditis caused by coxsackievirus B3. J Pathol. 2001;195:593-603.
50. Seo SK, Park HY, Choi JH, et al. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol. 2003; 171:576-583.
51. Cho HR, Kwon BS, Yagita H, et al. Blockade of 4-1BB (CD137)/ 4-1BB ligand interactions increases allograft survival. Transplant Int. 2004;17:351-361.